PURPOSE: Hypofractionated radiotherapy delivers larger daily doses of radiation and may increase the biologically effective dose delivered to the prostate. We conducted a randomized trial testing the hypothesis that dose-escalated, moderately hypofractionated intensity-modulated radiation therapy (HIMRT) improves prostate cancer control compared with conventionally fractionated IMRT (CIMRT) for men with localized prostate cancer. PATIENTS AND METHODS: Men were randomly assigned to 75.6 Gy in 1.8-Gy fractions delivered over 8.4 weeks (CIMRT) or 72 Gy in 2.4 Gy fractions delivered over 6 weeks (HIMRT, biologically equivalent to 85 Gy in 1.8-Gy fractions assuming prostate cancer α-to-β ratio of 1.5). Failure was defined as prostate-specific antigen (PSA) failure (nadir plus 2 ng/mL) or initiation of salvage therapy. Modified Radiation Therapy Oncology Group criteria were used to grade late (≥ 90 days after completion of radiotherapy) GI and genitourinary toxicity. RESULTS: Most of the 206 men (72%) had cT1, Gleason score 6 or 7 (99%), and PSA level ≤ 10 ng/mL (90%) disease. Androgen deprivation therapy was received by 24%. With a median follow-up of 8.5 years, men treated with HIMRT experienced fewer treatment failures (n = 10) than men treated with CIMRT (n = 21; P = .036). The 8-year failure rate was 10.7% (95% CI, 5.8% to 19.1%) with HIMRT and 15.4% (95% CI, 9.1% to 25.4%) with CIMRT. There was no difference in overall survival ( P = .39). There was a nonsignificant increase in late grade 2 or 3 GI toxicity with HIMRT (8-year 5.0% v 12.6%; P = .08). However, GI toxicity was only 8.6% when rectal volume receiving 65 Gy of HIMRT was ≤ 15%. Late genitourinary toxicity was similar ( P = .84). There was no grade 4 toxicity. CONCLUSION: The results of this randomized trial demonstrate superior cancer control for men with localized prostate cancer who receive dose-escalated moderately hypofractionation radiotherapy while shortening treatment duration.
PURPOSE: Hypofractionated radiotherapy delivers larger daily doses of radiation and may increase the biologically effective dose delivered to the prostate. We conducted a randomized trial testing the hypothesis that dose-escalated, moderately hypofractionated intensity-modulated radiation therapy (HIMRT) improves prostate cancer control compared with conventionally fractionated IMRT (CIMRT) for men with localized prostate cancer. PATIENTS AND METHODS: Men were randomly assigned to 75.6 Gy in 1.8-Gy fractions delivered over 8.4 weeks (CIMRT) or 72 Gy in 2.4 Gy fractions delivered over 6 weeks (HIMRT, biologically equivalent to 85 Gy in 1.8-Gy fractions assuming prostate cancer α-to-β ratio of 1.5). Failure was defined as prostate-specific antigen (PSA) failure (nadir plus 2 ng/mL) or initiation of salvage therapy. Modified Radiation Therapy Oncology Group criteria were used to grade late (≥ 90 days after completion of radiotherapy) GI and genitourinary toxicity. RESULTS: Most of the 206 men (72%) had cT1, Gleason score 6 or 7 (99%), and PSA level ≤ 10 ng/mL (90%) disease. Androgen deprivation therapy was received by 24%. With a median follow-up of 8.5 years, men treated with HIMRT experienced fewer treatment failures (n = 10) than men treated with CIMRT (n = 21; P = .036). The 8-year failure rate was 10.7% (95% CI, 5.8% to 19.1%) with HIMRT and 15.4% (95% CI, 9.1% to 25.4%) with CIMRT. There was no difference in overall survival ( P = .39). There was a nonsignificant increase in late grade 2 or 3 GI toxicity with HIMRT (8-year 5.0% v 12.6%; P = .08). However, GI toxicity was only 8.6% when rectal volume receiving 65 Gy of HIMRT was ≤ 15%. Late genitourinary toxicity was similar ( P = .84). There was no grade 4 toxicity. CONCLUSION: The results of this randomized trial demonstrate superior cancer control for men with localized prostate cancer who receive dose-escalated moderately hypofractionation radiotherapy while shortening treatment duration.
Authors: Mack Roach; Gerald Hanks; Howard Thames; Paul Schellhammer; William U Shipley; Gerald H Sokol; Howard Sandler Journal: Int J Radiat Oncol Biol Phys Date: 2006-07-15 Impact factor: 7.038
Authors: David J Brenner; Alvaro A Martinez; Gregory K Edmundson; Christina Mitchell; Howard D Thames; Elwood P Armour Journal: Int J Radiat Oncol Biol Phys Date: 2002-01-01 Impact factor: 7.038
Authors: D Watkins-Bruner; C Scott; C Lawton; J DelRowe; M Rotman; L Buswell; C Beard; D Cella Journal: Int J Radiat Oncol Biol Phys Date: 1995-11-01 Impact factor: 7.038
Authors: Usama Mahmood; Lawrence B Levy; Paul L Nguyen; Andrew K Lee; Deborah A Kuban; Karen E Hoffman Journal: J Urol Date: 2014-06-12 Impact factor: 7.450
Authors: W Robert Lee; James J Dignam; Mahul B Amin; Deborah W Bruner; Daniel Low; Gregory P Swanson; Amit B Shah; David P D'Souza; Jeff M Michalski; Ian S Dayes; Samantha A Seaward; William A Hall; Paul L Nguyen; Thomas M Pisansky; Sergio L Faria; Yuhchyau Chen; Bridget F Koontz; Rebecca Paulus; Howard M Sandler Journal: J Clin Oncol Date: 2016-04-04 Impact factor: 44.544
Authors: David P Dearnaley; Gordana Jovic; Isabel Syndikus; Vincent Khoo; Richard A Cowan; John D Graham; Edwin G Aird; David Bottomley; Robert A Huddart; Chakiath C Jose; John H L Matthews; Jeremy L Millar; Claire Murphy; J Martin Russell; Christopher D Scrase; Mahesh K B Parmar; Matthew R Sydes Journal: Lancet Oncol Date: 2014-02-26 Impact factor: 41.316
Authors: R Bischoff; M Chaloupka; T Westhofen; T Grimm; B Schlenker; P Weinhold; D Tilki; C G Stief; A Kretschmer Journal: Urologe A Date: 2019-05 Impact factor: 0.639
Authors: Vladimir Avkshtol; Karen J Ruth; Eric A Ross; Mark A Hallman; Richard E Greenberg; Robert A Price; Brooke Leachman; Robert G Uzzo; Charlie Ma; David Chen; Daniel M Geynisman; Mark L Sobczak; Eddie Zhang; Jessica K Wong; Alan Pollack; Eric M Horwitz Journal: J Clin Oncol Date: 2020-03-02 Impact factor: 44.544
Authors: Patricia Mae G Santos; Andrew R Barsky; Wei-Ting Hwang; Curtiland Deville; Xingmei Wang; Stefan Both; Justin E Bekelman; John P Christodouleas; Neha Vapiwala Journal: Cancer Date: 2019-09-10 Impact factor: 6.860
Authors: Nam P Nguyen; Vincent Vinh-Hung; Brigitta Baumert; Alice Zamagni; Meritxell Arenas; Micaela Motta; Pedro Carlos Lara; Arthur Sun Myint; Marta Bonet; Tiberiu Popescu; Te Vuong; Gokula Kumar Appalanaido; Lurdes Trigo; Ulf Karlsson; Juliette Thariat Journal: Cancers (Basel) Date: 2020-05-19 Impact factor: 6.639
Authors: Andreas Pettersson; Daniel Alm; Hans Garmo; Marie Hjelm Eriksson; Enrique Castellanos; Lennart Åström; Jon Kindblom; Anders Widmark; Adalsteinn Gunnlaugsson; Ingela Franck Lissbrant; Per Nilsson; Pär Stattin Journal: JNCI Cancer Spectr Date: 2020-02-14